Cotización MedinCell (EM) - MDCLF

MedinCell (EM) (MDCLF) Cotización

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

34.39

( - )

Postura de Compra

0.00

Postura de Venta

0.00

Volume Operado de la Acción

0.00 Rango del Día 0.00

6.9757 Rango de 52 semanas 34.39

Capitalización de Mercado [m]

1.235B

Precio Anterior

34.39

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

US$ 111,038

Acciones en circulación

35,904,117

Rendimiento del Dividendo (LTM)

Ratio Precio/Utilidad

-42.69

Beneficio por acción (BPA)

-0.63

turnover

32.44M

Beneficio neto

-19.95M

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophreni... MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France. Mostrar más

Sector

Healthcare

Industria

Biotechnology & Life Sciences

Sitio web

www.medincell.com

Sede

Jacou, France

Fundado

2026

MedinCell (EM) is listed in the Healthcare sector of the OTC Markets with ticker MDCLF. The last closing price for MedinCell (EM) was US$34.39. Over the last year, MedinCell (EM) shares have traded in a share price range of US$ 6.9757 to US$ 34.39.

MedinCell (EM) currently has 35,904,117 shares in issue. The market capitalisation of MedinCell (EM) is US$1.23 billion. MedinCell (EM) has a price to earnings ratio (PE ratio) of -42.69.

No hay noticias para mostrar aún.

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	34.39	34.39	34.39	0	0	CS
26	27.4143	392.997118569	6.9757	34.39	6.9757	56	34.39	CS
52	27.4143	392.997118569	6.9757	34.39	6.9757	89	13.30207692	CS
156	27.4046	392.312537578	6.9854	34.39	6.9746	864	7.43389735	CS
260	20.39	145.642857143	14	34.39	6.9746	1387	9.20560969	CS